...
首页> 外文期刊>Therapeutic advances in drug safety. >Minimizing anticholinergic drug prescribing in older hospitalized patients: a full audit cycle
【24h】

Minimizing anticholinergic drug prescribing in older hospitalized patients: a full audit cycle

机译:尽量减少老年住院患者的抗胆碱药处方:完整的审核周期

获取原文
           

摘要

Anticholinergic drugs are associated with poor outcomes in older patients but no specific intervention strategies aimed at reducing anticholinergic drug exposure have been described. To identify whether a consultant-led medication review targeting anticholinergics would reduce anticholinergic drug exposure [number of anticholinergic drugs and Anticholinergic Risk Scale (ARS) score]. The first phase of the audit included 70 consecutive admissions (mean age 84 years, 53 women). ARS score was calculated on admission and after initial consultant review. Re-audit was undertaken on another 70 consecutive admissions (mean age 83 years, 43 women) after introducing a system of informing the responsible consultant of the ARS score at their first review. Drugs with anticholinergic effects (n = 53) were prescribed preadmission to 45/140 (32%) of patients. Consultant geriatrician review reduced ARS scores (p = 0.01), especially following the introduction of the information system (p = 0.002). In the first arm of the audit, 51 (73%) patients had ARS of 0 after a consultant’s review compared with 47 (67%) patients on admission, whilst 67 (96%) patients had ARS of 2 or less after a consultant’s review compared with 63 (90%) patients on admission. In the second arm of the audit, 59 (84%) patients had ARS of 0 after a consultant’s review compared with 48 (69%) patients on admission, whilst 70 (100%) patients had ARS of 2 or less after a consultant’s review compared with 69 (99%) patients on admission. Anticholinergic drugs were either stopped, or their dose reduced, in 35% of patients in the first arm of the audit and in 73% of patients in the re-audit (odds ratio 5.0, 95% confidence interval 1.4–17.8). Consultant-led medication review (standard practice) was effective at reducing anticholinergic drug exposure in the acute setting. A system of alerting clinicians to patients prescribed anticholinergic medications further reduced anticholinergic drug exposure.
机译:抗胆碱药物与老年患者预后不良有关,但尚未描述旨在减少抗胆碱药物暴露的具体干预策略。为了确定以抗胆碱能药物为顾问的药物审查是否会减少抗胆碱能药物的暴露[抗胆碱能药物的数量和抗胆碱能风险量表(ARS)评分]。审核的第一阶段包括连续70次入场(平均年龄84岁,女性53位)。 ARS分数是在入院时和最初的顾问审查后计算的。在引入了在第一次审核时将负责任顾问的ARS分数通知系统后,又对连续70例入院(平均年龄83岁,女性43位)进行了重新审核。在45/140(32%)的患者中开具了允许抗胆碱作用的药物(n = 53)。咨询的老年科医生审查降低了ARS评分(p = 0.01),尤其是在引入信息系统之后(p = 0.002)。在审核的第一组中,经过顾问审核后,有51(73%)患者的ARS为0,而入院时为47(67%)患者,而经过顾问审核后的67(96%)患者,ARS为2以下相比之下,入院时有63名患者(90%)。在审核的第二阶段,经过顾问审核后,有59(84%)患者的ARS为0,而入院时为48(69%)患者,而经过顾问审核后的70(100%)患者,ARS为2或更低相比入院时有69名(99%)患者。在检查的第一组中有35%的患者停止了抗胆碱能药物或降低了剂量,在再次检查中有73%的患者停止了抗胆碱能药物(赔率5.0,95%置信区间1.4-17.8)。顾问指导的药物审查(标准做法)在减少急性环境中的抗胆碱能药物暴露方面有效。一个警告临床医生处方抗胆碱药的患者的系统进一步减少了抗胆碱药的暴露。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号